GIP Receptor Activity
GIP receptor activation contributes to glucose-dependent insulin secretion and metabolic regulation.
Glucose-dependent response SCIENTIFIC & MEDICAL INFORMATION
MAGIC Tirzepatide
A dual GIP & GLP-1 receptor agonist presented for healthcare professionals.
Educational and professional information only. Product-specific indications, dosing, storage and regulatory status must be confirmed against the applicable approved labeling.
GIPReceptor activity
GLP-1Receptor activity
1×Weekly administration
FOR HEALTHCAREPROFESSIONALS
✦
Dual pathwayGIP + GLP-1 activity
◉
Once weeklySubcutaneous administration
✓
Professional focusScience-led information
⌁
Evidence basedClinical research context
01 / OVERVIEW
What is Tirzepatide?
Tirzepatide is a once-weekly injectable medication that acts as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist.
01
Dual receptor activity
By activating both GIP and GLP-1 pathways, tirzepatide affects glucose-dependent insulin secretion, glucagon regulation, appetite, food intake and metabolic processes.
GIPGLP-1Metabolic pathways
Tirzepatide is used, depending on the approved indication and product labeling, together with appropriate diet and physical activity.
02 / PHARMACEUTICAL QUALITY
Advanced Pharmaceutical Quality
Magic Tirzepatide is a pharmaceutical product formulated with tirzepatide, an advanced therapeutic molecule intended for use under appropriate medical supervision.
The product is developed with a strong focus on quality, consistency, sterility, and manufacturing standards, with specifications designed to meet internationally recognized pharmaceutical quality requirements.
DE
Made in GermanyGerman-based specifications • International quality standards
DE
German Specifications – International Quality Standards
Magic Tirzepatide is manufactured according to German-based quality specifications and stringent pharmaceutical manufacturing principles, with emphasis on product consistency, quality control, and safety.
Every stage of production is subject to controlled quality procedures to help ensure the required standards of pharmaceutical quality and batch consistency.
Controlled processesQuality controlBatch consistencySafety focus
Manufacturing origin, certifications, specifications, and quality claims should be supported by the applicable regulatory documentation and certificates for the specific product and manufacturing facility.
03 / PHARMACOLOGY
Mechanism of Action
Tirzepatide activates both GIP and GLP-1 receptors. The combined activity of these pathways is central to its pharmacological profile.
GIPGLP-1
Dual Pathway
Combined GIP and GLP-1 activity contributes to improved glycemic control and, in approved obesity indications, clinically meaningful body-weight reduction.
Dual receptor agonismGLP-1 Receptor Activity
- Glucose-dependent insulin secretion
- Reduction of glucagon secretion
- Delayed gastric emptying
- Reduced appetite and food intake
04 / PRODUCT PRESENTATIONS
MAGIC Tirzepatide Presentations
Four presentations are shown in the supplied product artwork. Concentration and total vial content are not the same as an individualized prescribed dose.
PRESENTATION 01
5 mg/mL
15 mg / 3 mL
Product Information
- Active Ingredient
- Tirzepatide
- Strength
- 5 mg/mL
- Presentation
- 3 mL vial
- Route of Administration
- Subcutaneous use
- Use
- Under the supervision of a qualified healthcare professional
Quality & Safety
- Controlled manufacturing processes
- Raw-material quality control
- Product identity and potency testing
- Microbiological and sterility controls, where applicable
- Batch-to-batch consistency
PRESENTATION 02
10 mg/mL
30 mg / 3 mL
Product Information
- Active Ingredient
- Tirzepatide
- Strength
- 10 mg/mL
- Presentation
- 3 mL vial
- Route of Administration
- Subcutaneous use
- Use
- Under the supervision of a qualified healthcare professional
Quality & Safety
- Controlled manufacturing processes
- Raw-material quality control
- Product identity and potency testing
- Microbiological and sterility controls, where applicable
- Batch-to-batch consistency
PRESENTATION 03
15 mg/mL
45 mg / 3 mL
Product Information
- Active Ingredient
- Tirzepatide
- Strength
- 15 mg/mL
- Presentation
- 3 mL vial
- Route of Administration
- Subcutaneous use
- Use
- Under the supervision of a qualified healthcare professional
Quality & Safety
- Controlled manufacturing processes
- Raw-material quality control
- Product identity and potency testing
- Microbiological and sterility controls, where applicable
- Batch-to-batch consistency
PRESENTATION 04
30 mg/mL
90 mg / 3 mL
Product Information
- Active Ingredient
- Tirzepatide
- Strength
- 30 mg/mL
- Presentation
- 3 mL vial
- Route of Administration
- Subcutaneous use
- Use
- Under the supervision of a qualified healthcare professional
Quality & Safety
- Controlled manufacturing processes
- Raw-material quality control
- Product identity and potency testing
- Microbiological and sterility controls, where applicable
- Batch-to-batch consistency
Important: The concentration printed on a vial is not the same thing as the prescribed dose. The volume required for an individual dose must be determined from the applicable approved product labeling and the prescribed dose.
ADDITIONAL PRESENTATION
Magic Tirzepatide 60 mg / 3 mL
Each 3 mL vial contains a total of 60 mg of Tirzepatide, corresponding to a concentration of 20 mg/mL.
Product InformationTotal Strength per Vial: 60 mgFill Volume: 3 mLConcentration: 20 mg/mLPresentation: Vial / Multi-dose vialRoute: Subcutaneous administration
Strength Clarification
60 mg / 3 mL = 20 mg/mL. The stated strength refers to the total amount of Tirzepatide contained in the 3 mL vial, not 60 mg per milliliter.
05 / CLINICAL USES
Where Tirzepatide May Be Used
Indications vary by product and jurisdiction. The following summarizes approved-use contexts described in current U.S. labeling and clinical literature.
Type 2 Diabetes Mellitus
Tirzepatide can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, according to applicable labeling.
Chronic Weight Management
In approved settings, tirzepatide is used with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term.
Obstructive Sleep Apnea
Current U.S. labeling for ZEPBOUND includes treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. Product-specific authorization must be confirmed locally.
06 / ADMINISTRATION
How is Tirzepatide Administered?
Tirzepatide is administered by subcutaneous injection once weekly. It may generally be administered at any time of day, with or without food, according to the applicable prescribing information.
Common injection sites
01Abdomen
02Thigh
03Upper arm
Injection sites should be rotated regularly. Healthcare professionals should follow the specific Instructions for Use supplied with the applicable product.
07 / DOSE ESCALATION
Gradual Titration for Tolerability
For FDA-approved weight-management use, the ZEPBOUND prescribing information recommends a low starting dose followed by gradual escalation.
012.5 mgOnce weekly
First 4 weeks
First 4 weeks
→
025 mgOnce weekly
Initial maintenance option
Initial maintenance option
→
03+2.5 mgAfter ≥4 weeks
if appropriate & tolerated
if appropriate & tolerated
→
0415 mgMaximum recommended
once-weekly dose
once-weekly dose
Recommended weight-management maintenance doses:5 mg10 mg15 mgDose selection should be individualized according to response and tolerability.
08 / MISSED DOSE
When a Weekly Dose Is Missed
For the FDA-approved ZEPBOUND labeling:
≤ 4 daysAdminister as soon as possible within 96 hours.
> 4 daysSkip the missed dose and take the next dose on the regular day.
≥ 72 hoursDo not take two doses within 72 hours of each other.
09 / CLINICAL EVIDENCE
Clinical Research at a Glance
Selected findings from peer-reviewed trials. Outcomes vary between individuals and should not be interpreted as a guarantee of individual results.
Weight change
In SURMOUNT-1, mean weight change at week 72 was −15.0%, −19.5% and −20.9% with 5, 10 and 15 mg respectively, versus −3.1% with placebo.
Tirzepatide vs semaglutide
−20.2%Tirzepatide
VS
−13.7%Semaglutide
In adults with obesity without type 2 diabetes, tirzepatide produced greater mean weight reduction than semaglutide at week 72.
Glycemic control
Tirzepatide's glucose-dependent mechanism supports insulin secretion while reducing inappropriate glucagon secretion. Clinical studies have demonstrated significant improvements in HbA1c and body weight compared with several established therapies.
Treatment should always be individualized by a qualified healthcare professional.
10 / SAFETY PROFILE
Safety & Tolerability
Gastrointestinal adverse reactions are among the most frequently reported events, particularly during dose escalation.
Common adverse reactions
Nausea
Diarrhea
Decreased appetite
Vomiting
Constipation
Dyspepsia / abdominal discomfort
!
IMPORTANT
Warnings & Precautions
Tirzepatide caused thyroid C-cell tumors in rats. It is not known whether this effect occurs in humans. Contraindications include a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Report a neck mass, dysphagia, dyspnea or persistent hoarseness.
Acute pancreatitis has been reported. Persistent severe abdominal pain, especially with vomiting, requires prompt medical evaluation.
Acute gallbladder-related events, including gallstones and cholecystitis, have been associated with tirzepatide.
Severe gastrointestinal adverse reactions can occur. Tirzepatide is not recommended in patients with severe gastroparesis.
The risk may increase when tirzepatide is used with insulin or insulin secretagogues such as sulfonylureas.
Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported.
Drug-use considerations
Tirzepatide should not be combined with another tirzepatide-containing product or a GLP-1 receptor agonist unless specifically directed under an appropriate clinical protocol.
Storage & handling
Storage requirements must follow the specific product's approved labeling. Do not use product that has been improperly stored or exposed to conditions outside its approved instructions.
Medical supervision
Tirzepatide is a prescription medication. Treatment should be initiated and monitored by an appropriately qualified healthcare professional.
11 / PROFESSIONAL CARE
Clinical assessment matters.
Professional assessment may include medical history, current medications, weight and metabolic parameters, glycemic status when appropriate, gastrointestinal tolerability, treatment response and relevant contraindications.
Medical historyCurrent medicationsMetabolic parametersGlycemic statusTolerabilityContraindications
12 / REFERENCES
Professional Sources
Use current, product-specific prescribing information when making clinical decisions.
FDAZEPBOUND (tirzepatide) Prescribing InformationCurrent U.S. labeling source used for dosing, missed-dose, indications and safety sections.↗
NEJMTirzepatide Once Weekly for the Treatment of ObesitySURMOUNT-1, 72-week randomized clinical trial.↗
NEJMTirzepatide as Compared with Semaglutide for the Treatment of ObesitySURMOUNT-5, published 2025.↗
NEJMTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesSURPASS-2 clinical evidence.↗
13 / CONTACT US
Connect with MAGIC Tirzepatide
For product information, professional inquiries, documentation requests, or other healthcare-professional questions, please complete the form. Your message will be submitted to our contact email.
EMAILinfo@magic-tirzepatide.comFor Healthcare ProfessionalsPlease do not use this form for medical emergencies or urgent patient-care matters.
Important Professional Note
The information provided on this page is for educational and professional purposes only and does not replace approved prescribing information, medical evaluation or professional clinical judgment. Always consult the applicable approved product labeling before prescribing, dispensing, preparing or administering tirzepatide.